Hemogenyx Pharmaceuticals PLC Director/PDMR Shareholding (2753E)
July 03 2019 - 1:00AM
UK Regulatory
TIDMHEMO
RNS Number : 2753E
Hemogenyx Pharmaceuticals PLC
03 July 2019
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Director/PDMR Shareholding
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has
awarded 1,066,667 ordinary shares of GBP0.01 each to the Company's
CEO, Dr Vladislav Sandler, as a bonus in recognition of his
performance in bringing forward the new developments referred to in
recent announcements, as well as advancing the Company's core CDX
antibody and Hu-PHEC projects. Following the issue of shares, Dr
Sandler is beneficially interested in 116,635,362 ordinary shares
representing 32.29% of the enlarged share capital. The Concert
Party (as defined in the Company's prospectus dated 8 September
2017) now holds 229,829,175 ordinary shares representing 63.62%* of
the enlarged share capital.
Professor Sir Marc Feldmann, Chairman, commented, "I
congratulate Dr Sandler on behalf of the Board for the excellent
progress made in recent months. These achievements are particularly
notable given the Company's current size and the resources
available to it. In this context, it is also worth noting that Dr
Sandler has waived part of his director's remuneration. The
progress achieved by him and his team of scientists, and the
interest elicited from major biopharmaceutical companies, have
strengthened the Company's prospects, and will hopefully enable
shareholders to benefit substantially from our more diversified
product portfolio in the future."
*The Concert Party holding decreased by 11,692,863 ordinary
shares following the disposal by Plum Capital Limited of its entire
holding of ordinary shares in the Company on 12 October 2018.
An application has been made to the London Stock Exchange Main
Market and admission of the new shares to trading is expected on or
around 9 July 2019 ("Admission").
Total Voting Rights
Following Admission of the new shares, the Company will have
361,242,853 ordinary shares of GBP0.01 each in issue with voting
rights. This figure may then be used by shareholders in the Company
as the denominator for the calculation by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the
Financial Conduct Authority's Disclosure and Transparency
Rules.
The total voting rights figure includes an allotment of
4,008,504 ordinary shares to Cornell University announced on 5
October 2017 in partial satisfaction of a licence fee and 124,826
ordinary shares that were issued following an exercise of warrants
on 30 May 2018.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMR") and persons
closely associated with them ("PCA"):
1. Details of PDMR/person closely associated with them
a) Name Dr Vladislav Sandler
------------------------------ -----------------------------------
b) Position/status CEO/Director
------------------------------ -----------------------------------
c) Initial notification/ Initial notification
amendment
------------------------------ -----------------------------------
2. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
-------------------------------------------------------------------
a) Description of Ordinary shares of 1p of Hemogenyx
the financial Pharmaceuticals plc
instrument Identification code GB00BYX3WZ24
------------------------------ -----------------------------------
b) Nature of the Allotment of ordinary shares
transaction
------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP GBP0.03 1,066,667
----------
------------------------------ -----------------------------------
d) Aggregated information Price(s) Volume(s)
* Aggregated volume GBP GBP32,000.00 1,066,667
----------
* Price
------------------------------ -----------------------------------
e) Date of the transaction 28-06-2019
------------------------------ -----------------------------------
f) Place of the transaction London Stock Exchange
XLON
------------------------------ -----------------------------------
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Sir Marc Feldmann, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre, Soltan
Tagiev
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded
company (LSE: HEMO) headquartered in London, with its wholly-owned
US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located
at its state-of-the-art research facility in New York City and a
wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL,
located in Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBRGDRCSGBGCD
(END) Dow Jones Newswires
July 03, 2019 02:00 ET (06:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024